Public-private partnerships in advancing Ebola treatment pipeline

Currently, there are no FDA-approved vaccines or drugs for Ebola virus. The need for effective therapeutic approaches is increasingly vital, yet the research dollars have not been forthcoming. » Read how drug makers can be incentivized for developing these drugs

Study: Pneumococcal vaccine can decrease antibiotic-resistant infections in kids by 62%

The 13-valent pneumococcal conjugate vaccine (PCV13) not only prevents pneumococcal illness and death, but also dramatically decreases antibiotic-resistant infections in children by as much as 62%, according to a new study presented at IDWeek 2014. » Read about this study’s important health implications

Continuing Education

Motivational interviewing techniques for chronic disease management: Focus on cardiovascular disease

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists, particularly in the outpatient setting, regarding the clinical principles, techniques, and benefits of using motivational interviewing to improve cardiovascular outcomes in their patients.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT11-YXJ69.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

Drug Overview: Zykadia (ceritinib)

Zykadia (ceritinib) is a tyrosine kinase inhibitor that was approved by FDA on April 29, 2014, as a medication for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. Zykadia targets the inhibition of insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), ROS1, and is most active against ALK. » Drug's relevance, advantages and disadvantages and cost are discussed

• Read more on Ebola

• CDC committee endorses Pfizer pneumonia vaccine

RESOURCES

Latest Clinical News